18 kDa Translocator protein (TSPO) is upregulated in rat brain after peripheral nerve injury and downregulated by diroximel fumarate

• Published in: Brain, behavior, and immunity Vol. 123; pp. 11 - 27
• Main Authors: Cazuza, Rafael A., Zagrai, Sever M., Grieco, Anamaria R., Avery, Thomas D., Abell, Andrew D., Wey, Hsiao-Ying, Loggia, Marco L., Grace, Peter M.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.01.2025
• Subjects: Biomarker; Neuropathic pain; Nrf2; PET; Rat; TSPO; TSPO; Biomarker; Rat; Nrf2; PET; Neuropathic pain
• ISSN: 0889-1591; 1090-2139; 1090-2139
• DOI: 10.1016/j.bbi.2024.08.057

•Translocator protein 18 kDa (TSPO) is upregulated with neuroimmune signaling.•TSPO is upregulated in brains of male and female rats with peripheral nerve injury.•TSPO is expressed predominantly by microglia.•TSPO is downregulated by treatment with Nrf2 activator. Neuroimmune signaling is a key process underlying neuropathic pain. Clinical studies have demonstrated that 18 kDa translocator protein (TSPO), a putative marker of neuroinflammation, is upregulated in discrete brain regions of patients with chronic pain. However, no preclinical studies have investigated TSPO dynamics in the brain in the context of neuropathic pain and in response to analgesic treatments. We used positron emission tomography-computed tomography (PET-CT) and [18F]-PBR06 radioligand to measure TSPO levels in the brain across time after chronic constriction injury (CCI) of the sciatic nerve in both male and female rats. Up to 10 weeks post-CCI, TSPO expression was increased in discrete brain regions, including medial prefrontal cortex, somatosensory cortex, insular cortex, anterior cingulate cortex, motor cortex, ventral tegmental area, amygdala, midbrain, pons, medulla, and nucleus accumbens. TSPO was broadly upregulated across these regions at 4 weeks post CCI in males, and 10 weeks in females, though there were regional differences between the sexes. Using immunohistochemistry, we confirmed TSPO expression in these regions. We further demonstrated that TSPO was upregulated principally in microglia in the nucleus accumbens core, and astrocytes and endothelial cells in the nucleus accumbens shell. Finally, we tested whether TSPO upregulation was sensitive to diroximel fumarate, a drug that induces endogenous antioxidants via nuclear factor E2-related factor 2 (Nrf2). Diroximel fumarate alleviated neuropathic pain and reduced TSPO upregulation. Our findings indicate that TSPO is upregulated over the course of neuropathic pain development and is resolved by an antinociceptive intervention in animals with peripheral nerve injury.